Appendix 1: Studies included in Figures 2–8

Alderman EL, Levy JH, Rich JB, Nili M, Vidne B, Schaff H, et al. Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial. Journal of Thoracic & Cardiovascular Surgery 1998;116(5):716-30.

Alvarez JM, Quiney NF, McMillan D, Joscelyne K, Connelly T, Brady P, et al. The use of ultra-low-dose aprotinin to reduce blood loss in cardiac surgery. Journal of Cardiothoracic & Vascular Anesthesia 1995;9(1):29-33.

Alvarez JM, Jackson LR, Chatwin C, Smolich JJ. Low-dose postoperative aprotinin reduces mediastinal drainage and blood product use in patients undergoing primary coronary artery bypass grafting who are taking aspirin: a prospective, randomized, double-blind, placebo-controlled trial. Journal of Thoracic & Cardiovascular Surgery 2001;122(3):457-63.

Andreasen JJ, Nielsen C. Prophylactic tranexamic acid in elective, primary coronary artery bypass surgery using cardiopulmonary bypass. European Journal of Cardio-Thoracic Surgery 2004;26(2):311-7.

Armellin G, Casella S, Guzzinati S, Pasini L, Marcassa A, Giron G. Tranexamic acid in aortic valve replacement. Journal of Cardiothoracic & Vascular Anesthesia 2001;15(3):331-5.

Ashraf S, Tian Y, Cowan D, Nair U, Chatrath R, Saunders NR, et al. "Low-dose" aprotinin modifies hemostasis but not proinflammatory cytokine release. Annals of Thoracic Surgery 1997;63(1):68-73.

Asimakopoulos G, Kohn A, Stefanou DC, et al. Leukocyte integrin expression in patients undergoing cardiopulmonary bypass. Ann Thorac Surg 2000;69:1192-7.

Baele PL, Ruiz-Gomez J, Londot C, Sauvage M, Van Dyck MJ, Robert A. Systematic use of aprotinin in cardiac surgery: influence on total homologous exposure and hospital cost. Acta Anaesthesiologica Belgica 1992;43(2):103-12.

Bernet F, Carrel T, Marbet G, Skarvan K, Stulz P. Reduction of blood loss and transfusion requirements after coronary artery bypass grafting: similar efficacy of tranexamic acid and aprotinin in aspirin-treated patients. Journal of Cardiac Surgery 1999;14(2):92-7.

Bidstrup BP, Royston D, Sapsford RN, Taylor KM. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). Journal of Thoracic & Cardiovascular Surgery 1989;97(3):364-72.

Bidstrup BP, Underwood SR, Sapsford RN, Streets EM. Effect of aprotinin (Trasylol) on aorta-coronary bypass graft patency. Journal of Thoracic & Cardiovascular Surgery 1993;105(1):147-52.

Bidstrup BP, Hunt BJ, Sheikh S, Parratt RN, Bidstrup JM, Sapsford RN. Amelioration of the bleeding tendency of preoperative aspirin after aortocoronary bypass grafting. Annals of Thoracic Surgery 2000;69(2):541-7.

Blauhut B, Harringer W, Bettelheim P, Doran JE, Spath P, Lundsgaard-Hansen P. Comparison of the effects of aprotinin and tranexamic acid on blood loss and related variables after cardiopulmonary bypass. Journal of Thoracic & Cardiovascular Surgery 1994;108(6):1083-91.

Brown RS, Thwaites BK, Mongan PD. Tranexamic acid is effective in decreasing postoperative bleeding and transfusions in primary coronary artery bypass operations: A double-blind, randomized, placebo-controlled trial. Anesthesia & Analgesia 1997;85(5):963-970.

Carrera A, Martinez MV, Garcia Guiral M, Herrero E, Peral A, Planas A. Utilizacion de altas dosis de aprotinina en cirugia cardiaca - High doses of aprotinin in cardiac surgery. Revista Espanola de Anestesiologia y Reanimacion 1994;41:13-9.

Casas JI, Zuazu-Jausoro I, Mateo J, Oliver A, Litvan H, Muniz-Diaz E, et al. Aprotinin versus desmopressin for patients undergoing operations with cardiopulmonary bypass. A double-blind placebo-controlled study. Journal of Thoracic & Cardiovascular Surgery 1995;110(4 Pt 1):1107-17.

Casati V, Guzzon D, Oppizzi M, Cossolini M, Torri G, Calori G, Alfieri O. Hemostatic effects of aprotinin, tranexamic acid and epsilon-aminocaproic acid in primary cardiac surgery. Annals of Thoracic Surgery 1999;68(6):2252-6.

Casati V, Guzzon D, Oppizzi M, Bellotti F, Franco A, Gerli C, et al. Tranexamic acid compared with high-dose aprotinin in primary elective heart operations: effects on perioperative bleeding and allogeneic transfusions. Journal of Thoracic & Cardiovascular Surgery 2000;120(3):520-7.

Cicek S, Demirkilic U, Kuralay E, Ozal E, Tatar H. Postoperative Aprotinin: Effect on blood loss and transfusion requirements in cardiac operations. Annals of Thoracic Surgery 1996a;61:1372-6.

Cicek S, Demirkilic U, Ozal E, Kuralay E, Bingol H, Tatar H, Ozturk OY. Postoperative use of aprotinin in cardiac operations: An alternative to its prophylactic use. Journal of Thoracic & Cardiovascular Surgery 1996b;112(6):1462-7.

Cicekcioglu F, Cagli K, Emir M, et al. Effects of minimal dose aprotinin on blood loss and fibrinolytic system-complement activation in coronary artery bypass grafting surgery. J Card Surg 2006;21:336-41.

Coffey A, Pittmam J, Halbrook H, Fehrenbacher J, Beckman D, Hormuth D, et al. The use of tranexamic acid to reduce postoperative bleeding following cardiac surgery: A double-blind randomized trial. American Surgeon 1995;61(7):566-8.

Cohen G, Ivanov J, Weisel RD, Rao V, Mohabeer MK, Mickle DA. Aprotinin and dipyridamole for the safe reduction of postoperative blood loss. Annals of Thoracic Surgery 1998;65(3):674-83.

Cosgrove DM, 3d, Heric B, Lytle BW, Taylor PC, Novoa R, Golding LA, et al. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. Annals of Thoracic Surgery 1992;54(6):1031-6.

D'Ambra MN, Akins CW, Blackstone EH, Bonney SL, Cohn LH, Cosgrove DM, et al. Aprotinin in primary valve replacement and reconstruction: a multicenter, double-blind, placebo-controlled trial. Journal of Thoracic & Cardiovascular Surgery 1996;112(4):1081-9.

Daily PO, Lamphere JA, Dembitsky WP, Adamson RM, Dans NF. Effect of prophylactic epsilon-aminocaproic acid on blood loss and transfusion requirements in patients undergoing first-time coronary artery bypass grafting. A randomized, prospective, double-blind study. Journal of Thoracic & Cardiovascular Surgery 1994;108(1):99-106.

DelRossi AJ, Cernaianu AC, Botros S, Lemole GM, Moore R. Prophylactic treatment of postperfusion bleeding using EACA. Chest 1989;96(1):27-30.

Dietrich W, Barankay A, Hahnel C, Richter JA. High-dose aprotinin in cardiac surgery: three years' experience in 1,784 patients. Journal of Cardiothoracic & Vascular Anesthesia 1992;6(3):324-7.

Dietrich W, Dilthey G, Spannagl M, Jochum M, Braun SL, Richter JA. Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celite- and kaolin-activated clotting time in heparin-pretreated patients undergoing open-heart surgery. A double-blind, placebo-controlled study. Anesthesiology 1995;83(4):679-89.

Dignan RJ, Law DW, Seah PW, Manganas CW, Newman DC, Grant PW, et al. Ultra-low dose aprotinin decreases transfusion requirements and is cost effective in coronary operations. Annals of Thoracic Surgery 2001;71(1):158-63.

Diprose P, Herbertson MJ, O'Shaughnessy D, Deakin CD, Gill RS. Reducing allogeneic transfusion in cardiac surgery: a randomized double-blind placebo-controlled trial of antifibrinolytic therapies used in addition to intra-operative cell salvage. British Journal of Anaesthesia 2005;94(3):271-8.

Dryden PJ, O'Connor JP, Jamieson WR, Reid I, Ansley D, Sadeghi H, et al. Tranexamic acid reduces blood loss and transfusion in reoperative cardiac surgery. Canadian Journal of Anaesthesia 1997;44(9):934-41.

Englberger L, Markart P, Eckstein FS, Immer FF, Berdat PA, Carrel TP. Aprotinin reduces blood loss in off-pump coronary artery bypass (OPCAB) surgery. European Journal of Cardio-Thoracic Surgery 2002a;22(4):545-51.

Englberger L, Kipfer B, Berdat PA, Nydegger UE, Carrel TP. Aprotinin in coronary operation with cardiopulmonary bypass: does "low-dose" aprotinin inhibit the inflammatory response? Annals of Thoracic Surgery 2002b;73(6):1897-904.

Feindt P, Seyfert U, Volkmer I, et al. Is there a phase of hypercoagulability when aprotinin is used in cardiac surgery? Eur J Cardiothorac Surg 1994;8:308-13.

Fergusson DA, Hébert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008;358:2319-31.

Golanski R, Golanski J, Chizynski K, Iwaszkiewicz A, Zaslonka J, Pietrucha T, et al. Low doses of aprotinin in aortocoronary bypass surgery - advantages and disadvantages. Medical Science Monitor 2000;6(4):722-8.

Gott JP, Cooper WA, Schmidt FE, et al. Modifying risk for extracorporeal circulation: trial of four anti-inflammatory strategies. Ann Thorac Surg 1998;66:747-53.

Green D, Sanders J, Eiken M, Wong CA, Frederiksen J, Joob A, et al. Recombinant aprotinin in coronary artery bypass graft operations. Journal of Thoracic & Cardiovascular Surgery 1995;110(4 Pt 1):963-70.

Harder MP, Eijsman L, Roozendaal KJ, van Oeveren W, Wildevuur CR. Aprotinin reduces intraoperative and postoperative blood loss in membrane oxygenator cardiopulmonary bypass. Annals of Thoracic Surgery 1991;51(6):936-41.

Hardy JF, Desroches J, Belisle S, Perrault J, Carrier M, Robitaille D. Low-dose aprotinin infusion is not clinically useful to reduce bleeding and transfusion of homologous blood products in high-risk cardiac surgical patients. Canadian Journal of Anaesthesia 1993;40(7):625-31.

Hardy JF, Belisle S, Dupont C, Harel F, Robitaille D, Roy M, et al. Prophylactic tranexamic acid and epsilon-aminocaproic acid for primary myocardial revascularization. Annals of Thoracic Surgery 1998;65(2):371-6.

Hayashida N, Isomura T, Sato T, Maruyama H, Kosuga K, Aoyagi S. Effects of minimal-dose aprotinin on coronary artery bypass grafting. Journal of Thoracic & Cardiovascular Surgery 1997;114(2):261-9.

Hekmat K, Zimmermann T, Kampe S, Kasper SM, Weber HJ, Geissler HJ, et al. Impact of tranexamic acid vs. aprotinin on blood loss and transfusion requirements after cardiopulmonary bypass: a prospective, randomised, double-blind trial. Current Medical Research & Opinion 2004;20(1):121-6.

Horrow JC, Van Riper DF, Strong MD, Brodsky I, Parmet JL. Hemostatic effects of tranexamic acid and desmopressin during cardiac surgery. Circulation 1991;84(5):2063-70.

Jamieson WRE, Dryden PJ, O'Connor JP, Sadeghi H, Ansley DM, Merrick PM, et al. Beneficial effect of both tranexamic acid and aprotinin on blood loss reduction in reoperative valve replacement surgery. Circulation 1997;96(9 SUPPL):II96-101.

Jares M, Vanek T, Straka Z, Brucek P. Tranexamic acid reduces bleeding after off-pump coronary artery bypass grafting. Journal of Cardiovascular Surgery 2003;44(2):205-8.

Kalangos A, Tayyareci G, Pretre R, Di Dio P, Sezerman O. Influence of aprotinin on early graft thrombosis in patients undergoing myocardial revascularization. European Journal of Cardiothoracic Surgery 1994;8(12):651-6.

Karski JM, Teasdale SJ, Norman P, Carroll J, VanKessel K, Wong P, et al. Prevention of bleeding after cardiopulmonary bypass with high-dose tranexamic acid. Double-blind, randomized clinical trial. Journal of Thoracic & Cardiovascular Surgery 1995;110(3):835-42.

Karski J, Djaiani G, Carroll J, Iwanochko M, Seneviratne P, Liu P, et al. Tranexamic acid and early saphenous vein graft patency in conventional coronary artery bypass graft surgery: a prospective randomized controlled clinical trial. Journal of Thoracic & Cardiovascular Surgery 2005;130(2):309-14.

Katoh J, Tsuchiya K, Sato W, Nakajima M, Iida Y. Additional postbypass administration of tranexamic acid reduces blood loss after cardiac operations. Journal of Thoracic & Cardiovascular Surgery 1997;113(4):802-4.

Katsaros D, Petricevic M, Snow NJ, Woodhall DD, Van Bergen R. Tranexamic acid reduces postbypass blood use: a double-blinded, prospective, randomized study of 210 patients. Annals of Thoracic Surgery 1996;61(4):1131-5.

Kipfer B, Englberger L, Gygax E, Nydegger U, Carrel T. Is reduced systemic heparinization justified with heparin-bonded bypass circuits in cardiac surgery? Experience with and without aprotinin. Transfusion & Apheresis Science 2003;29(1):17-24.

Klein M, Keith PR, Dauben HP, Schulte HD, Beckmann H, Mayer G, Elert O, Gams E. Aprotinin counterbalances an increased risk of peri-operative hemorrhage in CABG patients pre-treated with Aspirin. European Journal of Cardio-Thoracic Surgery 1998;14(4):360-366.

Kluger R, Olive DJ, Stewart AB, Blyth CM. Epsilon-aminocaproic acid in coronary artery bypass graft surgery: preincision or postheparin?. Anesthesiology 2003;99(6):1263-1269.

Koster A, Huebler S, Merkle F, Hentschel T, Grundel M, Krabatsch T, Tambeur L, Praus M, Habazettl H, Kuebler WM, Kuppe H. Heparin-level-based anticoagulation management during cardiopulmonary bypass: a pilot investigation on the effects of a half-dose aprotinin protocol on postoperative blood loss and hemostatic activation and inflammatory response. Anesthesia & Analgesia 2004;98(2):285-290.

Kuepper F, Dangas G, Mueller-Chorus A, Kulka PM, Zenz M, Wiebalck A. Fibrinolytic activity and bleeding after cardiac surgery with cardiopulmonary bypass and low-dose aprotinin therapy. Blood Coagulation & Fibrinolysis 2003;14(2):147-153.

Kuitunen A, Hiippala S, Vahtera E, Rasi V, Salmenpera M. The effects of aprotinin and tranexamic acid on thrombin generation and fibrinolytic response after cardiac surgery. Acta Anaesthesiologica Scandinavica 2005;49(9):1272-1279.

Kuitunen AHS. Tranexamic acid does not correct the haemostatic impairment caused by hydroxyethyl starch (200 kDa/0.5) after cardiac surgery. Blood Coagul Fibrinolysis 2006;17:639-45.

Kunt AS, Darcin OT, Aydin S, Demir D, Selli C, Andac MH. Mini-dose pump-prime aprotinin inhibited enhanced fibrinolytic activity and reduced blood loss and transfusion requirements after coronary artery bypass surgery. Journal of Thrombosis & Thrombolysis 2005;19(3):197-200.

Lab M, Welz A, Kochs M, Mayer G, Schwandt M, Hannekum A. Aprotinin in elective primary bypass surgery. European Journal of Cardio-thoracic Surgery 1995;9:206-10.

Landymore RW, Murphy JT, Lummis H, Carter C. The use of low-dose aprotinin, epsilon-aminocaproic acid or tranexamic acid for prevention of mediastinal bleeding in patients receiving aspirin before coronary artery bypass operations. European Journal of Cardio-Thoracic Surgery 1997;11:798-800.

Lemmer JH, Jr, Stanford W, Bonney SL, Breen JF, Chomka EV, Eldredge WJ, Holt WW, Karp RB, Laub GW, Lipton MJ, et al. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. A multicenter, randomized, double-blind, placebo-controlled study. Journal of Thoracic & Cardiovascular Surgery 1994;107(2):543-51.

Lemmer JH, Jr, Dilling EW, Morton JR, Rich JB, Robicsek F, Bricker DL, Hantler CB, Copeland JG, 3rd, Ochsner JL, Daily PO, et al. Aprotinin for primary coronary artery bypass grafting: a multicenter trial of three dose regimens. Annals of Thoracic Surgery 1996;62(6):1659-67.

Levy JH, Pifarre R, Schaff HV, Horrow JC, Albus R, Spiess B, Rosengart TK, Murray J, Clark RE, Smith P. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation 1995;92(8):2236-44.

Appendix to: Henry D, Carless P, Fergusson D, et al. The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis. *CMAJ* 2009;180:183-93.

Liu B, Belboul A, Radberg G, Tengborn L, Dernevik L, Roberts D, William-Olsson G. Effect of reduced aprotinin dosage on blood loss and use of blood products in patients undergoing cardiopulmonary bypass. Scandinavian Journal of Thoracic & Cardiovascular Surgery 1993;27(3-4):149-55.

Luo J, Huang Y, Lan H. Effect of aprotinin on the red cell immunity in cardiopulmonary bypass. J Tongji Med Univ 1998;18:97-100.

Maccario M, Fumagalli C, Deangelis R, Delfino R, Pergolo A, Dottori V, Barberis L. Comparison between low and high doses of aprotinin in heart surgery [Italian]. Minerva Anestesiologica 1994;60(6):315-20.

Mansour EE, Mustafa B. Aprotinin versus tranexamic acid in patients receiving aspirin and undergoing off-pump coronary artery bypass. Egyptian Journal of Anaesthesia 2004;20(3):229-236.

Misfeld M, Dubbert S, Eleftheriadis S, Siemens HJ, Wagner T, Sievers HH. Fibrinolysis-adjusted perioperative low-dose aprotinin reduces blood loss in bypass operations. Annals of Thoracic Surgery 1998;66(3):792-799.

Mohr R, Goor DA, Lusky A, Lavee J. Aprotinin prevents cardiopulmonary bypass-induced platelet dysfunction. A scanning electron microscope study. Circulation 1992;86(5:Suppl):II405-9.

Mongan PD, Brown RS, Thwaites BK. Tranexamic acid and aprotinin reduce postoperative bleeding and transfusions during primary coronary revascularization. Anesthesia & Analgesia 1998;87(2):258-265.

Moran SV, Lema G, Medel J, Irarrazaval MJ, Zalaquett R, Garayar B, Flaskamp R. Comparison of two doses of aprotinin in patients receiving aspirin before coronary bypass surgery. Perfusion 2000;15(2):105-110.

Murkin JM, Lux J, Shannon NA, Guiraudon GM, Menkis AH, McKenzie FN, Novick RJ. Aprotinin significantly decreases bleeding and transfusion requirements in patients receiving aspirin and undergoing cardiac operations. Journal of Thoracic & Cardiovascular Surgery 1994;107(2):554-61.

Murphy GJ, Mango E, Lucchetti V, et al. A randomized trial of tranexamic acid in combination with cell salvage plus a meta-analysis of randomized trials evaluating tranexamic acid in off-pump coronary artery bypass grafting. J Thorac Cardiovasc Surg 2006;132:475-80.

Nuttall GA, Oliver WC, Ereth MH, Santrach PJ, Bryant SC, Orszulak TA, Schaff HV. Comparison of blood-conservation strategies in cardiac surgery patients at high risk for bleeding. Anesthesiology 2000;92(3):674-682.

Parvizi R, Azarfarin R, Hassanzadeh S. Ultra-low dose aprotinin effects on reducing the need for blood transfusion in cardiac surgery. Saudi Med J 2007;28:49-53.

Poston RS, White C, Gu J, Brown J, Gammie J, Pierson RN, et al. Aprotinin shows both hemostatic and antithrombotic effects during off-pump coronary artery bypass grafting. Annals of Thoracic Surgery 2006;81(1):104-11.

Rao BH, Saxena N, Chauhan S, Sashikanth M. Use of E-Aminocaproic acid in the management of aspirin related postoperative bleeding in patients undergoing coronary revascularization. Journal of Anaesthesiology Clinical Pharmacology 1999;15(3):261-264.

Rhydderch RD, Khan B, Saleh A, et al. Single dose aprotinin in routine cardiac surgery. Middle East J Anesthesiol 1993;12:287-97.

Rocha E, Hidalgo F, Llorens R, Melero JM, Arroyo JL, Paramo JA. Randomized study of aprotinin and DDAVP to reduce postoperative bleeding after cardiopulmonary bypass surgery. Circulation 1994;90(2):921-7.

Rodrigus IE, Vermeyen KM, De Hert SG, Amsel BJ, Walter PJ. Efficacy and safety of aprotinin in aortocoronary bypass and valve replacement operations: a placebo-controlled randomized double-blind study. Perfusion 1996;11(4):313-8.

Royston D, Bidstrup BP, Taylor KM, Sapsford RN. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 1987;2(8571):1289-91.

Santamaria A, Mateo J, Oliver A, Litvan H, Murillo J, Souto JC, Fontcuberta J. The effect of two different doses of aprotinin on hemostasis in cardiopulmonary bypass surgery: similar transfusion requirements and blood loss. Haematologica 2000;85(12):1277-1284.

Santos ATL, Kalil RAK, Bauemann C, Pereira JB, Nesralla IA. A randomized, double-blind, and placebo-controlled study with tranexamic acid of bleeding and fibrinolytic activity after primary coronary artery bypass grafting. Brazilian Journal of Medical & Biological Research 2006;39(1):63-9.

Schweizer A, Hohn L, Morel DR, Kalangos A, Licker M. Aprotinin does not impair renal haemodynamics and function after cardiac surgery. British Journal of Anaesthesia 2000;84(1):16-22.

Shore-Lesserson L, Reich DL, Vela-Cantos F, Ammar T, Ergin MA. Tranexamic acid reduces transfusions and mediastinal drainage in repeat cardiac surgery. Anesthesia & Analgesia 1996;83(1):18-26.

Speekenbrink RG, Vonk AB, Wildevuur CR, Eijsman L. Hemostatic efficacy of dipyridamole, tranexamic acid, and aprotinin in coronary bypass grafting. Annals of Thoracic Surgery 1995;59(2):438-42.

Stammers AH, Huffman S, Alonso A, Fristoe LW, Hill G, Casebeer D, Diego RP, Song Z. The antiinflammatory effects of aprotinin in patients undergoing cardiac surgery with cardiopulmonary bypass. Journal of Extra-Corporeal Technology 1997;29(3):114-122.

Swart MJ, Gordon PC, Hayse-Gregson PB, Dyer RA, Swanepoel AL, Buckels NJ, Schall R, Odell JA. High-dose aprotinin in cardiac surgery--a prospective, randomized study. Anaesthesia & Intensive Care 1994;22(5):529-33.

Taggart DP, Djapardy V, Naik M, Davies A. A randomized trial of aprotinin (Trasylol) on blood loss, blood product requirement, and myocardial injury in total arterial grafting. Journal of Thoracic & Cardiovascular Surgery 2003;126(4):1087-1094.

Trinh-Duc P, Wintrebert P, Boulfroy D, Albat B, Thevenet A, Roquefeuil B. Comparison of the effects of epsilon-aminocaproic acid and aprotinin on intra- and postoperative bleeding in heart surgery. [French]. Annales de Chirurgie 1992;46(8):677-683.

Van der Linden J, Lindvall G, Sartipy U. Aprotinin decreases postoperative bleeding and number of transfusions in patients on clopidogrel undergoing coronary artery bypass graft surgery: A double-blind, placebo-controlled, randomized clinical trial. Circulation 2005;112(Suppl I):I-276-I-280.

Vander Salm TJ, Kaur S, Lancey RA, Okike ON, Pezzella AT, Stahl RF, Leone L, Li J-M, Valeri CR, Michelson AD. Reduction of bleeding after heart operations through the prophylactic use of epsilon-aminocaproic acid. Journal of Thoracic & Cardiovascular Surgery 1996;112(4):1098-1107.

Wei M, Jian K, Guo Z, et al. Effects of half-dose aprotinin in off-pump coronary artery bypass grafting. World J Surg 2006;30:1108-14.

Wei M, Jian K, Guo Z, Wang L, Jiang D, Zhang L, Tarkka M. Tranexamic acid reduces postoperative bleeding in off-pump coronary artery bypass grafting. Scandinavian Cardiovascular Journal 2006;40(2):105-109.

Wendel HP, Heller W, Michel J, Mayer G, Ochsenfahrt C, Graeter U, Schulze J, Hoffmeister HM, Hoffmeister HE. Lower cardiac troponin T levels in patients undergoing cardiopulmonary bypass and receiving high-dose aprotinin therapy indicate reduction of perioperative myocardial damage. Journal of Thoracic & Cardiovascular Surgery 1995;109(6):1164-72.

Wong BI, McLean RF, Fremes SE, Deemar KA, Harrington EM, Christakis GT, Goldman BS. Aprotinin and tranexamic acid for high transfusion risk cardiac surgery. Annals of Thoracic Surgery 2000;69(3):808-816.

Zabeeda D, Medalion B, Sverdlov M, Ezra S, Schachner A, Ezri T, Cohen AJ. Tranexamic acid reduces bleeding and the need for blood transfusion in primary myocardial revascularization. Annals of Thoracic Surgery 2002;74(3):733-738.

Appendix to: Henry D, Carless P, Fergusson D, et al. The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis. *CMAJ* 2009;180:183-93.